AN UNBIASED VIEW OF TELAPREVIR

 1 prior regimen of chemotherapy for State-of-the-art breast most cancers and through the full trial, earlier exposure to any FGFR inhibitor, important surgical procedure or radiotherapy in just four months ahead of very first dose of review procedure and having strong inhibitors or inducers of CYP3A4 or CYP2D6. Any of the next cardiac requiremen